Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

Teddi Mellencamp's health update revealed she's experiencing a symptom she believes could be from immunotherapy. Read.

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

Teddi's followers have her back. The post Teddi Mellencamp Experiencing ‘Severe Anxiety’ Amid Immunotherapy Treatment ...

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...

Cancer treatments can speed up aging in survivors, according to research, which can contribute to a person's risk for ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.